An antibody can bind so readily near a tumor's blood vessels that little reaches cells farther away. Strong binding and even delivery throughout a tumor are different properties.
Antibody uptake can be concentrated near accessible binding sites, leaving heterogeneous intratumoral distribution. A primary antibody-drug conjugate study altered antibody coadministration in a mouse xenograft model and improved penetration and efficacy without increasing the payload dose. This establishes a delivery mechanism in that model, not a dosing recommendation for patients. Distribution, retained binding and effective intracellular exposure need to be considered together.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Antigen expression and treatment response, Evidence from measurement to patient benefit, Antibody-drug conjugate (ADC).
Shares Experimental and clinical drug exposure, Evidence from measurement to patient benefit.
Shares Antigen expression and treatment response, Evidence from measurement to patient benefit.
Shares Experimental and clinical drug exposure, Evidence from measurement to patient benefit.
Shares Experimental and clinical drug exposure, Evidence from measurement to patient benefit.
Shares Evidence from measurement to patient benefit, Antibody-drug conjugate (ADC).
Shares Epitope, Antibody-drug conjugate (ADC).
Shares Epitope, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/